U.S. Markets open in 6 hrs 28 mins
  • S&P Futures

    4,250.50
    +4.75 (+0.11%)
     
  • Dow Futures

    34,500.00
    +38.00 (+0.11%)
     
  • Nasdaq Futures

    14,018.00
    +23.75 (+0.17%)
     
  • Russell 2000 Futures

    2,336.50
    +2.60 (+0.11%)
     
  • Crude Oil

    71.30
    +0.39 (+0.55%)
     
  • Gold

    1,861.70
    -17.90 (-0.95%)
     
  • Silver

    27.91
    -0.24 (-0.86%)
     
  • EUR/USD

    1.2109
    +0.0003 (+0.0242%)
     
  • 10-Yr Bond

    1.4620
    0.0000 (0.00%)
     
  • Vix

    15.65
    -0.45 (-2.80%)
     
  • GBP/USD

    1.4108
    -0.0009 (-0.0621%)
     
  • USD/JPY

    109.6700
    +0.0350 (+0.0319%)
     
  • BTC-USD

    39,610.91
    +4,262.08 (+12.06%)
     
  • CMC Crypto 200

    986.52
    +44.71 (+4.75%)
     
  • FTSE 100

    7,134.06
    0.00 (0.00%)
     
  • Nikkei 225

    29,161.80
    +213.07 (+0.74%)
     

Announcing: Cantel Medical (NYSE:CMD) Stock Increased An Energizing 168% In The Last Year

·3 min read

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Cantel Medical Corp. (NYSE:CMD). Its share price is already up an impressive 168% in the last twelve months. On top of that, the share price is up 11% in about a quarter. But this move may well have been assisted by the reasonably buoyant market (up 9.1% in 90 days). Unfortunately the longer term returns are not so good, with the stock falling 22% in the last three years.

See our latest analysis for Cantel Medical

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During the last year Cantel Medical grew its earnings per share (EPS) by 126%. The share price gain of 168% certainly outpaced the EPS growth. So it's fair to assume the market has a higher opinion of the business than it a year ago. The fairly generous P/E ratio of 79.82 also points to this optimism.

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

earnings-per-share-growth
earnings-per-share-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of Cantel Medical's earnings, revenue and cash flow.

A Different Perspective

It's nice to see that Cantel Medical shareholders have received a total shareholder return of 168% over the last year. That's better than the annualised return of 6% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 3 warning signs with Cantel Medical (at least 1 which doesn't sit too well with us) , and understanding them should be part of your investment process.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.